Table I.
Baseline patient and disease characteristics in patients treated with vosaroxin administered as a short (≤10 min) intravenous infusion
| Schedule A* | Schedule B† | Schedule C72‡ | Schedule C90§ | All patients | |
|---|---|---|---|---|---|
| Patients treated, n | 29 | 35 | 29 | 20 | 113 |
| Median age (range), years | 75 (61–89) | 75 (64–87) | 70 (61–84) | 78 (66–88) | 75 (61–89) |
| Gender, n (%) | |||||
| Male | 19 (66) | 23 (66) | 14 (48) | 17 (85) | 73 (65) |
| Female | 10 (35) | 12 (34) | 15 (52) | 3 (15) | 40 (35) |
| AML subtype,¶ n (%) | |||||
| With characteristic genetic abnormalities | 0 | 2 (6) | 2 (7) | 1 (5) | 5 (4) |
| With multilineage dysplasia | 12 (41) | 8 (23) | 6 (21) | 9 (45) | 35 (31) |
| Alkylating agent–related AML and MDS | 2 (7) | 2 (6) | 0 | 3 (15) | 7 (6) |
| Not otherwise categorized | 15 (52) | 22 (63) | 19 (66) | 7 (35) | 63 (56) |
| Missing | 0 | 1 (3) | 2 (7) | 0 | 3 (3) |
| Adverse prognostic factors, n (%) | |||||
| Age ≥70 years | 22 (76) | 27 (77) | 15 (52) | 17 (85) | 81 (72) |
| AHD | 11 (38) | 10 (29) | 7 (24) | 7 (35) | 35 (31) |
| ECOG PS 2 | 4 (14) | 4 (11) | 9 (31) | 3 (15) | 20 (18) |
| I/U cytogenetics | 27 (93) | 28 (80) | 28 (97) | 19 (95)** | 102 (90) |
| ≥2 risk factors | 25 (86) | 27 (77) | 24 (83) | 17 (85) | 93 (82) |
AHD, antecedent haematological disease; AML, acute myeloid leukaemia; ECOG PS, Eastern Cooperative Oncology Group performance status; I/U, intermediate/unfavourable; MDS, myelodysplastic syndrome.
*
72 mg/m2 on days 1, 8, and 15.
†
72 mg/m2 on days 1 and 8.
‡
72 mg/m2 on days 1 and 4.
§
90 mg/m2 on days 1 and 4.
¶
At diagnosis, by World Health Organization criteria (Vardiman et al, 2009).
**
Cytogenetic data are missing for one patient in this cohort.